nach oben

Breast Cancer Research

Erschienen in:

01.06.2009 | Viewpoint

Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?

verfasst von: Bryan P Schneider, George W Sledge Jr

Erschienen in: Breast Cancer Research | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these preclinical studies, and should they affect our willingness to explore anti-VEGF therapy in the adjuvant setting?

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007, 357: 2666-2676. 10.1056/NEJMoa072113.CrossRefPubMed

Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, Tomczak P, Taran T, Harbeck N, Steger GG: Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO [abstract]. J Clin Oncol. 2008, 26: LBA1011-

Slamon D, Gomez H, Kabbinavar F, Amit O, Richie M, Pandite L, Goodman V: Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2- positive advanced or metastatic breast cancer [abstract]. J Clin Oncol. 2008, 26: 1016-10.1200/JCO.2007.15.4849.CrossRef

Pegram M, Chan D, Dichmann RA, Tan-Chiu E, Yeon C, Durna L, Lin LS, Slamon D: Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer [abstract]. Breast Cancer Res Treat. 2006, 100: 3039-

Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009, 15: 232-239. 10.1016/j.ccr.2009.01.021.CrossRefPubMedPubMedCentral

Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS: Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA. 2007, 104: 17069-17074. 10.1073/pnas.0708148104.CrossRefPubMedPubMedCentral

Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006, 116: 2610-2621. 10.1172/JCI24612.CrossRefPubMedPubMedCentral

Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD: Phase II study of sunitinib malate, an oral multi-targeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008, 26: 1810-1816. 10.1200/JCO.2007.14.5375.CrossRefPubMed

Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009, 15: 220-231. 10.1016/j.ccr.2009.01.027.CrossRefPubMedPubMedCentral

10.

Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD, ECOG 2100: Association of VEGF and VEGFR-2 genetic polymorphisms with outcome in E2100. J Clin Oncol. 2008, 26: 4672-4678. 10.1200/JCO.2008.16.1612.CrossRefPubMedPubMedCentral

Titel: Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?
verfasst von: Bryan P Schneider
George W Sledge Jr
Publikationsdatum: 01.06.2009
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 3/2009
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr2250

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer

Gene expression in murine mammary epithelial stem cell-like cells shows similarities to human breast cancer gene expression

Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors

Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours

Co-incidental increase in gene copy number of ERBB2 and LRIG1 in breast cancer

Immunohistochemical characterization of subtypes of male breast carcinoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie